Main Article Content
Abstract
Background. The second generation anti-cyclic citrullinated peptide test (CCP2) displays sensitivity comparable to that of rheumatoid factor (RF) (approximately 80%) but with superior specificity (98%) . Several observations have indicated that early rheumatoid arthritis (RA) patients with positive anti-CCP may develop a more erosive disease than those without anti-CCP.
Objective. The purpose of this cross-sectional study was to investigate the correlation between anti-CCP antibodies and clinical and laboratory parameters and radiological joint destruction in RA patients.
Methods. We studied 31 patients with RA fulfilling the 1987 revised criteria of American College of Rheumatology in Rheumatology Clinic of Saiful Anwar General Hospital, Malang, Indonesia. Clinical parameters were collected such as age, sex, visual analog scale,
disease duration and diseases activity score (DAS28-3(CRP)). Laboratory parameters were WBC, hemoglobin, platelet count, erythrocyte sedimentation rate, and Creactive protein. Analyzed autoantibody profiles were RF and anti-CCP (ELISA methode). Radiological joint
destruction was evaluated from bilateral postero-anterior manus x ray (Sharp score).
Results. Anti-CCP antibodies were detected in 48.4% of RA patients with mean antibody concentration was 291.24±143.67 (range 16-523.8) units. Anti CCP level was significantly correlated with duration of RA (month) (p=0.04, r=0.371), RF level (p=0.002, r=0.542) and
Sharp score (p=0.048, r=0.358), but was not significantly correlated with other clinical and laboratory parameters.
Conclusion. Anti-CCP level was correlated with duration of disease, RF, and Sharp score.
Article Details
References
- Waldenburger JM, Firestein GS. Rheumatoid arthritis: epidemiology,
- pathology, and pathogenesis. In: Klippel JH, Stone JH, Crofford LJ,
- White PH, editors. Primer on rheumatic diseases. 13th ed. New York:
- Springer; 2008. p. 122-31.
- Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes
- JM, Breedveld FC, et al. The diagnostic properties of rheumatoid
- arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis
- Rheum 2000;43:155-63.
- Vasishta A. Diagnosing early-onset rheumatoid arthritis: the role of
- anti-CCP antibodies. Am Clin Lab 2002;21:34-6.
- Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic
- accuracy of the anti citrulline antibody assay for rheumatoid arthritis.
- Clin Chem 2001;47:1089-93.
- Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to
- diagnose rheumatoid arthritis early: a prediction model for persistent
- (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
- Jansen AL, van der Horst-Bruinsma I, van Schaardenburg, D, van de
- Stadt RJ, de Koning, Dijkmans BA. Rheumatoid factor and antibodies
- to cyclic citrullinated peptide differentiated rheumatoid arthritis from
- undifferentiated polyarthritis in patients with early arthritis. J Rheumatol
- ;29:2074-6.
- Pruijn GJM, Vossenaar ER, Drijfhout JW, van Venrooij WJ, Zendman
- AJW. Anti-CCP antibody detection facilitates early diagnosis and
- prognosis of rheumatoid arthritis. Current Rheumatology Reviews
- ;1:1-7.
- van Jaarsveld CH, ter Borg EJ, Jacobs JW, Schellekens GA, GmeligMeyling FH, van Booma-Frankfor C, et al. The prognostic value of
- the antiperinuclear factor, anti-citrullinated peptide antibodies and
- rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatology
- ;17:689-97.
- Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T.
- Prognostic laboratory markers of joint damage in rheumatoid arthritis.
- Ann Rheum Dis 2005;64:196-201.
- van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA,
- Breedveld FC, Verweij CL, et al. Auto-antibodies to cyclic citrullinated
- peptides predict progression to rheumatoid arthritis in patients with
- undifferentiated arthritis: a prospective cohort study. Arthritis Rheum
- ;50:709-15.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper
- NS, et al. The American Rheumatism Association 1987 revised criteria
- for the classification of rheumatoid arthritis. Arthritis Rheum 1988;
- :315-24.
- Fransen J, Stucki G, van Riel PLCM. DAS28 in rheumatoid arthritis
- measures. Arthritis Rheum 2003;49:214-24.
- Guerrero AV, Villaseñor CP. Evaluación radiográfica del daño
- anatómico en la artritis reumatoide. [Radiographic evaluation of
- anatomical damage in rheumatoid arthritis] Revista Colombiana de
- Reumatologia 2006;13:214-27.
- Lipsky PE. Rheumatoid arthritis. In: Fauci AS, Kasper DL, Longo DL,
- Braunwald E, Hauser SL, Jameson JL, editors. Harrison’s principle of internal medicine. 17th ed. New York: McGraw-Hill; 2008. p. 2083-92.
- Suryana BPP. Faktor-faktor risiko beratnya gangguan fungsional dan
- kerusakan sendi secara radiologis pada arthritis rheumatoid. [Risk
- factors of the severity of functional impairment and radiological joint
- damage in rheumatoid arthritis] Specialist thesis. Brawijaya University;
- Shahrir M, Shahdan M, Shahid M, Sulaiman W, Mokhtar AM, Othman
- M, et al. Multicentre survey of rheumatoid arthritis patients from
- Ministry of Health Rheumatology Centers in Malaysia. Inern Journ of
- Rheum Dis 2008;11:287-92.
- Wakitani S, Murata N, Toda R, Ogawa R, Kaneshige T, Nishimura Y, et
- al. The relationship between HLA-DRB1 alleles and disease subsets
- of rheumatoid arthritis in Japanese. Br J rheum 1997;36:630-6.
- Serdaroglu M, Cakirbay H, Deger O, Cengiz S, Kul S. The association
- of anti-CCP antibodies with disease activity in rheumatoid arthritis.
- Rheumatol Int 2008;28:965-70.
- Sanmarti R, Gomez A, Ercilla G, Gratacos J, Larrosa M, Suris X, et al.
- Radiological progression in early rheumatoid arthritis after DMARDS:
- a one-year follow-up study in a clinical setting. Rheumatology
- ;42:1044–9.
- Vitteqoc O, Pouplin S, Krzanowska K, Jouen-Beades F, Menard
- DF, Gayet A, et al. Rheumatoid factor is the strongest predictor
- of radiological progression of rheumatoid arthritis in a three-year
- prospective study in community-recruited patients. Rheumatology
- ;42:939-46.
- Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben
- D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies
- in early rheumatoid arthritis: a randomized trial. Ann Intern Med
- ;146:406-15.
- Jansen LMA, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BAC. Predictors of radiographic joint damage in
- patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:924-7.
- Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois
- A, et al. Anticitrullinated protein/peptide antibody assays in early
- rheumatoid arthritis for predicting five year radiographic damage. Ann
- Rheum Dis 2003;62:120-6.
- Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody
- test predicts the disease course during years in early rheumatoid
- arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9.
- Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction
- of radiological outcome in early rheumatoid arthritis in clinical
- practice: role of antibodies to citrullinated peptides. Ann Rheum Dis
- ;63:1090-5.
- Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients
- with rheumatic disease. Ann Rheum Dis 2003;62:870-4.
- Avouac J, Gossec L, Dougados M. Diagnostic and predictive value
- of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a
- systematic literature review. Ann Rheum Dis 2006;65:845-51.
- Houssien DA, Jonsson T, Davies E, Scott DL. Rheumatoid factor
- isotypes, disease activity and the outcome of rheumatoid arthritis:
- comparative effects of different antigens. Scand J Rheumatol
- ;27:46-53.
- van der Helm-van Mil AHM, Verpoort KN, Breeveld FC, Toes REM,
- Huizinga TWJ. Antibodies to citrullinated proteins and differences
- in clinical progression of rheumatoid arthritis. Arthritis Res Ther
- ;7:949-58.
- Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke
- K. Diagnostic and clinical value of anti-cyclic citrullinated peptide
- antibodies compared with rheumatoid factor isotypes in rheumatoid
- arthritis. Ann Rheum Dis 2004;63:1079-84.
- Vencovsky J, Machacek M, Sedova L, Kafkova J, Gatterova J,
- Pesakova V, et al. Autoantibodies can be prognostic markers of
- an erosive disease in early rheumatoid arthritis. Ann Rheum Dis
- ;62:427-30.
- Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen
- FH, van’t Hof M, et al. The prognostic value of anti-cyclic citrullinated
- peptide antibodies in patients with recent-onset rheumatoid arthritis.
- Arthritis Rheum 2000;43:1831-5.
- De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE,
- Veys EM, et al. Rheumatoid factor, but not anti-citrullinated protein antibodies, is modulated by infliximab treatment in Rheumatoid Arthritis.
- Ann Rheum Dis 2005;64:299-302.
- Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, et al. Decrease of anti-cyclic citrullinated peptide antibodies
- and rheumatoid factor following anti-TNFα therapy (infliximab) in
- rheumatoid arthritis is associated with clinical improvement. Ann
- Rheum Dis 2004; 63:1218-21.
- Ronnelid J, Wick MC, Lampa J. Longitudinal analysis of citrullinated
- protein/peptide antibodies (anti-CP) during 5 year follow up in early
- rheumatoid arthritis: anti-CP status predicts worse disease activity and
- greater radiological progression. Ann Rheum Dis 2005; 64(12)